Niyati Prasad
60 Science Park Square
Brighton, ENG BN19SB, United Kingdom
Brighton, ENG BN19SB, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
ETD001, a long-acting inhaled ENaC blocker, is well tolerated in a first human, healthy participant trial.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: August 27, 2025
Prognostic biomarkers for idiopathic pulmonary fibrosis: findings from ISABELA clinical trials.
Journal: ERJ open research
Published: July 01, 2025
An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis.
Journal: ERJ open research
Published: August 30, 2023
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.
Journal: JAMA
Published: May 09, 2023
A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: June 09, 2022
Control of moderate-to-severe asthma with randomized ciclesonide doses of 160, 320 and 640 μg/day.
Journal: Journal of asthma and allergy
Published: March 24, 2017
Randomized Double-Blind Controlled Trial of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease.
Journal: American journal of respiratory and critical care medicine
Published: February 02, 2017
Chronic obstructive pulmonary disease in China: the potential role of indacaterol.
Journal: Journal of thoracic disease
Published: July 10, 2013
Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
Journal: Respirology (Carlton, Vic.)
Published: November 30, 2011
Showing 1-10 of 10
Last Updated: 09/26/2026